Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013006813
pages 137-164

The Immune System in the Pathogenesis of Ovarian Cancer

Bridget Charbonneau
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Ellen L. Goode
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Kimberly R. Kalli
Division of Oncology, Mayo Clinic, Rochester, MN 55905
Keith L. Knutson
Department of Immunology, Mayo Clinic, Rochester, MN 55905
Melissa S. DeRycke
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905

RESUMO

Clinical outcomes in ovarian cancer are heterogeneous even when considering common features such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration into tumor and host characteristics. One compelling host characteristic is the immune response to ovarian cancer. While several studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease, recent genetic and protein analyses also suggest a role in disease incidence. Recent studies also show that anti-tumor immunity is often negated by immune suppressive cells present in the tumor microenvironment. These suppressive immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, future research into immunotherapy targeting ovarian cancer will likely become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression or by disrupting critical cytokine networks.


Articles with similar content:

Microenvironmental Hypoxia Orchestrating the Cell Stroma Cross Talk, Tumor Progression and Antitumor Response
Critical Reviews™ in Immunology, Vol.31, 2011, issue 5
Muhammad Zaeem Noman, Yosra Messai, Thibault Carre, Salem Chouaib, Bassam Janji, Meriem Hasmim, Intissar Akalay, Marine Meron
Inflammation Versus Adaptive Immunity in Cancer Pathogenesis
Critical Reviews™ in Oncogenesis, Vol.15, 2009, issue 1-2
Einar Martin Aandahl, Sheraz Yaqub
Signaling Pathways in Pancreatic Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 2
Meir Preis , Murray Korc
The Hepatic Immune System
Critical Reviews™ in Immunology, Vol.22, 2002, issue 1
Frank Leithauser, Mary Jo Wick, Jorg Reimann
Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Jeanne Tie , Jayesh Desai